The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses.

Researchers discovered a neutralizing monoclonal antibody that potentially acts as a potent universal coronavirus therapy against SARS-CoV-2 and all its variants of concern, including Beta, Gamma, Delta, Epsilon and Omicron.

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chances of death, according to a new study from UTHealth Houston and other institutions.

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substantially within 3 months, according to new clinical trial data. The findings, published today in Cell Reports Medicine, are from a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial was led by NIAID's Infectious Diseases Clinical Research Consortium.

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and when it might be necessary for individuals to get an additional booster shot.

Now, a team of scientists led by faculty at the Yale School of Public Health and the University of North Carolina at Charlotte has an answer: strong protection following vaccination is short-lived.

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccine is effective in protecting the elderly population in long-term care facilities from the Omicron variant. The groundbreaking study included approximately 40,000 elderly Israelis living in institutions supervised by the

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of damaged nerves after spinal trauma.

The research, published in Clinical and Translational Medicine, used cell and animal models to demonstrate that when taken orally the candidate drug, known as AZD1390, can block the response to DNA damage in nerve cells and promote regeneration of damaged nerves, so restoring sensory and motor function after spinal injury.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus. The experimental vaccine is manufactured by Moderna, Inc., (Cambridge, Massachusetts) and was developed in collaboration with NIAID's Vaccine Research Center. It is based on a messenger RNA (mRNA) platform - a technology used in several approved COVID-19 vaccines.